TABLE 2

Plasma pharmacokinetic parameters after oral or intravenous administration of vinorelbine at 10 mg/kg

Data are means ± S.D.; n = 4 to 6 for oral and n = 4 for intravenous administration.

	Strain
	WT	Mdr1a/1b(−/−)	Cyp3a(−/−)	Mdr1a/1b/Cyp3a(−/−)
Oral vinorelbine
AUC_0–24, h · mg⁻¹ · l⁻¹	0.25 ± 0.10	0.86 ± 0.37^*	0.54 ± 0.15^*	0.84 ± 0.22^*
C_max, mg/l	0.04 ± 0.02	0.45 ± 0.07^**	0.11 ± 0.03^*	0.33 ± 0.13^*
T_max, h	0.25	0.25	1	0.25
Intravenous vinorelbine
AUC_0–24, h · mg⁻¹ · l⁻¹	1.62 ± 0.27	3.70 ± 0.35^**	2.50 ± 0.14^**	1.17 ± 0.04^*
C_max, mg/l	6.30 ± 0.97	2.72 ± 0.24^**	4.01 ± 0.23^**	8.55 ± 0.31^**
T_max, h	15.4 ± 6.7	23.2 ± 10.2	21.6 ± 6.1	71.8 ± 19.1^*
Intravenous 4′-O-deacetylvinorelbine
AUC_0–24, h · mg⁻¹ · l⁻¹	0.40 ± 0.05	1.45 ± 0.14^**	2.02 ± 0.02^**	4.46 ± 0.31^**
C_max, mg/l
T_max, h	2.01 ± 0.30	5.15 ± 0.46^**	4.52 ± 0.14^**	5.63 ± 0.29^**
AUC_i.v. 4′-O-deacetylvinorelbine/AUC_i.v. vinorelbine
Exposure ratio	0.25	0.39	0.81	3.8